<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736801</url>
  </required_header>
  <id_info>
    <org_study_id>LO-1111</org_study_id>
    <nct_id>NCT00736801</nct_id>
  </id_info>
  <brief_title>Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma</brief_title>
  <official_title>Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this
      trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF
      concentrations will be assessed in patients with asthma. The investigators hypothesize that
      salmeterol impacts on BDNF concentrations in patients with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BDNF concentrations in serum, platelets and plasma</measure>
    <time_frame>2006 - 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airway hyperresponsiveness</measure>
    <time_frame>2006 - 2007</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol and Salmeterol / Fluticasone</intervention_name>
    <description>Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Serevent</other_name>
    <other_name>Viani</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years, a physician's diagnosis of allergic asthma

          -  A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite)

          -  A pre-bronchodilator forced expiratory volume in the first second (FEV1) &gt; 80 % of the
             predicted value (% predicted), a provocative concentration of histamine causing a 20 %
             fall in FEV1 (PC20) of &lt; 8 mg histamine / ml

        Exclusion Criteria:

          -  No regular treatment (only short-acting inhalers on demand were allowed)

          -  No history of or evidence for any other chronic disease than asthma

          -  No history of smoking, absence of any signs or symptoms of an infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann C. Virchow, MD, FCCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lommatzsch M, Schloetcke K, Klotz J, Schuhbaeck K, Zingler D, Zingler C, Schulte-Herbr√ºggen O, Gill H, Schuff-Werner P, Virchow JC. Brain-derived neurotrophic factor in platelets and airflow limitation in asthma. Am J Respir Crit Care Med. 2005 Jan 15;171(2):115-20. Epub 2004 Oct 29.</citation>
    <PMID>15516533</PMID>
  </reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>August 20, 2008</last_update_submitted>
  <last_update_submitted_qc>August 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. med. Marek Lommatzsch</name_title>
    <organization>University of Rostock</organization>
  </responsible_party>
  <keyword>Airway hyperresponsiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

